Citigroup
MLYS icon

Citigroup’s Mineralys Therapeutics MLYS Stock Holding History

Citigroup’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Buy
99,332
+84,247
+558% +$2.31M ﹤0.01% 2705
2026
Q1 		$409K Sell
15,085
-3,230
-18% -$94.7K ﹤0.01% 3663
2025
Q4 		$665K Sell
18,315
-144,853
-89% -$5.81M ﹤0.01% 3406
2025
Q3 		$6.19M Buy
163,168
+136,050
+502% +$2.94M ﹤0.01% 1827
2025
Q2 		$367K Buy
27,118
+6,125
+29% +$88.8K ﹤0.01% 3789
2025
Q1 		$333K Sell
20,993
-2,371
-10% -$27.3K ﹤0.01% 3895
2024
Q4 		$288K Buy
23,364
+1,391
+6% +$18.2K ﹤0.01% 4175
2024
Q3 		$266K Buy
21,973
+14,214
+183% +$172K ﹤0.01% 4149
2024
Q2 		$90.8K Buy
7,759
+3,803
+96% +$47.9K ﹤0.01% 4258
2024
Q1 		$51.1K Buy
3,956
+145
+4% +$1.79K ﹤0.01% 4615
2023
Q4 		$32.8K Buy
3,811
+3,805
+63,417% +$29.9K ﹤0.01% 4737
2023
Q3 		$57 Sell
6
-4,148
-100% -$54.1K ﹤0.01% 5511
2023
Q2 		$70.8K Buy
+4,154
New +$62.1K ﹤0.01% 4425

Other funds holding MLYS

AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Citigroup's MLYS Position: Q2 2026 in Review

Citigroup increased its Mineralys Therapeutics (MLYS) stake by 558% in Q2 2026, buying an estimated $2.31M and bringing the position to 99,332 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2705.

Citigroup first reported a position in MLYS in Q2 2023 and has held it in 13 quarters since. The position peaked at $6.19M in Q3 2025. 32 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Citigroup held 99,332 shares of Mineralys Therapeutics worth $2.68M as of Q2 2026.
  • Citigroup bought 84,247 Mineralys Therapeutics shares in Q2 2026, an estimated $2.31M.
  • Mineralys Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2705 holding.
  • Citigroup first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Citigroup's Mineralys Therapeutics position peaked at $6.19M in Q3 2025.
  • 32 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.